IDEAS home Printed from https://ideas.repec.org/r/wly/hlthec/v24y2015i10p1289-1301.html
   My bibliography  Save this item

The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature

Citations

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Opportunity costs, marginal productivity, and cost-effectiveness thresholds: what are they and how are they related?
    by Rita Faria, Jessica Ochalek, jameslomas88 in The Academic Health Economists' Blog on 2020-09-23 06:00:00

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Sebastian Himmler & Jannis Stöckel & Job van Exel & Werner B. F. Brouwer, 2021. "The value of health—Empirical issues when estimating the monetary value of a quality‐adjusted life year based on well‐being data," Health Economics, John Wiley & Sons, Ltd., vol. 30(8), pages 1849-1870, August.
  2. Fischer, Barbara & Telser, Harry & Zweifel, Peter & von Wyl, Viktor & Beck, Konstantin & Weber, Andreas, 2023. "The value of a QALY towards the end of life and its determinants: Experimental evidence," Social Science & Medicine, Elsevier, vol. 326(C).
  3. Hentschker, C. & Wübker, A., 2016. "The impact of technology diffusion in health care markets - Evidence from heart attack treatment," Health, Econometrics and Data Group (HEDG) Working Papers 16/29, HEDG, c/o Department of Economics, University of York.
  4. Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for timing when assessing health-related policies," LSE Research Online Documents on Economics 100038, London School of Economics and Political Science, LSE Library.
  5. Marije E. Hagendijk & Simon Schans & Cornelis Boersma & Maarten J. Postma & Simon Pol, 2021. "Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(6), pages 991-999, August.
  6. Jaithri Ananthapavan & Marj Moodie & Andrew J. Milat & Rob Carter, 2021. "Systematic Review to Update ‘Value of a Statistical Life’ Estimates for Australia," IJERPH, MDPI, vol. 18(11), pages 1-17, June.
  7. Laura Pirhonen & Kristian Bolin & Elisabeth Hansson Olofsson & Andreas Fors & Inger Ekman & Karl Swedberg & Hanna Gyllensten, 2019. "Person-Centred Care in Patients with Acute Coronary Syndrome: Cost-Effectiveness Analysis Alongside a Randomised Controlled Trial," PharmacoEconomics - Open, Springer, vol. 3(4), pages 495-504, December.
  8. Himmler, Sebastian & Jonker, Marcel & van Krugten, Frédérique & Hackert, Mariska & van Exel, Job & Brouwer, Werner, 2022. "Estimating an anchored utility tariff for the well-being of older people measure (WOOP) for the Netherlands," Social Science & Medicine, Elsevier, vol. 301(C).
  9. Borsenberger, Claire & Cremer, Helmuth & Joram, Denis & Lozachmeur, Jean-Marie & Malavolti, Estelle, 2023. "Testing for fragility: a valuable public policy and an opportunity for postal operators," TSE Working Papers 23-1433, Toulouse School of Economics (TSE).
  10. Kailu Wang & Xiaopeng Guo & Siyue Yu & Lu Gao & Zihao Wang & Huijuan Zhu & Bing Xing & Shuyang Zhang & Dong Dong, 2021. "Mapping of the acromegaly quality of life questionnaire to ED-5D-5L index score among patients with acromegaly," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1381-1391, December.
  11. Mello, Marco & Moscelli, Giuseppe, 2022. "Voting, contagion and the trade-off between public health and political rights: Quasi-experimental evidence from the Italian 2020 polls," Journal of Economic Behavior & Organization, Elsevier, vol. 200(C), pages 1025-1052.
  12. Corinna Hentschker & Ansgar Wübker, 2020. "Quasi-experimental evidence on the effectiveness of heart attack treatment in Germany," Applied Economics, Taylor & Francis Journals, vol. 52(50), pages 5531-5545, October.
  13. Ian Ross & Giulia Greco & Charles Opondo & Zaida Adriano & Rassul Nala & Joe Brown & Robert Dreibelbis & Oliver Cumming, 2022. "Measuring and valuing broader impacts in public health: Development of a sanitation‐related quality of life instrument in Maputo, Mozambique," Health Economics, John Wiley & Sons, Ltd., vol. 31(3), pages 466-480, March.
  14. Bardey, David & De Donder , Philippe & Zaporozhets , Vera, 2024. "The Health Technology Assessment Approach of The Economic Value of Diagnostic Test: A Literature Review," Documentos CEDE 21041, Universidad de los Andes, Facultad de Economía, CEDE.
  15. Armantier, Olivier & Filippin, Antonio & Neubauer, Michael & Nunziata, Luca, 2022. "The expected price of keeping up with the Joneses," Journal of Economic Behavior & Organization, Elsevier, vol. 200(C), pages 1203-1220.
  16. De Donder, Philippe & Bardey, David & Zaporozhets, Vera, 2024. "The Health Technology Assessment Approach of the Economic Value of Diagnostic Tests - A Literature Review," TSE Working Papers 24-1508, Toulouse School of Economics (TSE).
  17. Wei Hsu & Chih-Hao Yang & Wen-Ping Fan, 2021. "A Study of Patients’ Willingness to Pay for a Basic Outpatient Copayment and Medical Service Quality in Taiwan," IJERPH, MDPI, vol. 18(12), pages 1-12, June.
  18. Björn Sund & Mikael Svensson, 2018. "Estimating a constant WTP for a QALY—a mission impossible?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(6), pages 871-880, July.
  19. Jessica Ochalek & James Lomas & Karl Claxton, 2015. "Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data," Working Papers 122cherp, Centre for Health Economics, University of York.
  20. Shafrin, Jason & Skornicki, Michelle & Brauer, Michelle & Villeneuve, Julie & Lees, Michael & Hertel, Nadine & Penrod, John R. & Jansen, Jeroen, 2018. "An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?," Health Policy, Elsevier, vol. 122(6), pages 607-613.
  21. David D. Kim & Gregory F. Guzauskas & Caroline S. Bennette & Anirban Basu & David L. Veenstra & Scott D. Ramsey & Josh J. Carlson, 2020. "Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment," PharmacoEconomics, Springer, vol. 38(2), pages 171-179, February.
  22. Jessica Ochalek & Karl Claxton & Paul Revill & Mark Sculpher & Alexandra Rollinger, 2016. "Supporting the development of an essential health package: principles and initial assessment for Malawi," Working Papers 136cherp, Centre for Health Economics, University of York.
  23. S. Olofsson & U.-G. Gerdtham & L. Hultkrantz & U. Persson, 2019. "Value of a QALY and VSI estimated with the chained approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(7), pages 1063-1077, September.
  24. Sebastian Himmler & Job Exel & Werner Brouwer, 2020. "Estimating the monetary value of health and capability well-being applying the well-being valuation approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(8), pages 1235-1244, November.
  25. Charles E Phelps & Chris Cinatl, 2021. "Estimating optimal willingness to pay thresholds for cost‐effectiveness analysis: A generalized method," Health Economics, John Wiley & Sons, Ltd., vol. 30(7), pages 1697-1702, July.
  26. Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An, 2018. "Future Directions for Cost-effectiveness Analyses in Health and Medicine," Medical Decision Making, , vol. 38(7), pages 767-777, October.
  27. Claxton, Karl & Asaria, Miqdad & Chansa, Collins & Jamison, Julian & Lomas, James & Ochalek, Jessica & Paulden, Mike, 2019. "Accounting for Timing when Assessing Health-Related Policies," Journal of Benefit-Cost Analysis, Cambridge University Press, vol. 10(S1), pages 73-105, April.
  28. A. Mavrodi & V. Aletras & A. Spanou & D. Niakas, 2017. "Eliciting the Monetary Value of a Quality-Adjusted Life Year in a Greek Outpatient Department in Times of Economic Austerity," PharmacoEconomics - Open, Springer, vol. 1(4), pages 291-300, December.
  29. Moscelli, G.; & Sayli, M.; & Blanden, J.; & Mello, M.; & Castro-Pires, H.; & Bojke, C.;, 2023. "Non-monetary interventions, workforce retention and hospital quality: evidence from the English NHS," Health, Econometrics and Data Group (HEDG) Working Papers 23/13, HEDG, c/o Department of Economics, University of York.
  30. Huang, Li & Frijters, Paul & Dalziel, Kim & Clarke, Philip, 2018. "Life satisfaction, QALYs, and the monetary value of health," Social Science & Medicine, Elsevier, vol. 211(C), pages 131-136.
  31. Sebastian Himmler & Jannis Stöckel & Job van Exel & Werner Brouwer, 2020. "The Value of Health - Empirical Issues when Estimating the Monetary Value of a QALY Based on Well-Being," SOEPpapers on Multidisciplinary Panel Data Research 1101, DIW Berlin, The German Socio-Economic Panel (SOEP).
  32. Kamran Bagheri Lankarani & Sulmaz Ghahramani & Najmeh Moradi & Hadi Raeisi Shahraki & Farhad Lotfi & Behnam Honarvar, 2018. "Willingness-to-Pay for One Quality-Adjusted Life-Year: A Population-Based Study from Iran," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 837-846, December.
  33. Attema, Arthur & Frasch, Jona & L'Haridon, Olivier, 2020. "Multivariate risk preferences in the QALY model," MPRA Paper 103339, University Library of Munich, Germany.
  34. Afentoula G. Mavrodi & Vassilis H. Aletras, 2019. "Preliminary Results of a Healthcare Contingent Valuation Study in Greece," International Journal of Finance, Insurance and Risk Management, International Journal of Finance, Insurance and Risk Management, vol. 9(3-4), pages 3-16.
  35. Christian R. C. Kouakou & Thomas G. Poder, 2022. "Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(2), pages 277-299, March.
  36. James K. Hammitt, 2023. "Consistent valuation of a reduction in mortality risk using values per life, life year, and quality‐adjusted life year," Health Economics, John Wiley & Sons, Ltd., vol. 32(9), pages 1964-1981, September.
  37. Miller, Ray & Chin, Sayorn & Sedai, Ashish Kumar, 2022. "The welfare cost of late-life depression," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 15-36.
  38. Ahlert, Marlies & Breyer, Friedrich & Schwettmann, Lars, 2016. "How you ask is what you get: Framing effects in willingness-to-pay for a QALY," Social Science & Medicine, Elsevier, vol. 150(C), pages 40-48.
  39. Sara Olofsson & Ulf G. Gerdtham & Lars Hultkrantz & Ulf Persson, 2019. "Dread and Risk Elimination Premium for the Value of a Statistical Life," Risk Analysis, John Wiley & Sons, vol. 39(11), pages 2391-2407, November.
  40. Werner Brouwer & Pieter Baal & Job Exel & Matthijs Versteegh, 2019. "When is it too expensive? Cost-effectiveness thresholds and health care decision-making," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(2), pages 175-180, March.
  41. Christina Greenaway & Iuliia Makarenko & Claire Nour Abou Chakra & Balqis Alabdulkarim & Robin Christensen & Adam Palayew & Anh Tran & Lukas Staub & Manish Pareek & Joerg J. Meerpohl & Teymur Noori & , 2018. "The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review," IJERPH, MDPI, vol. 15(9), pages 1-24, September.
  42. Grisolía, José M. & Longo, Alberto & Hutchinson, George & Kee, Frank, 2018. "Comparing mortality risk reduction, life expectancy gains, and probability of achieving full life span, as alternatives for presenting CVD mortality risk reduction: A discrete choice study of framing ," Social Science & Medicine, Elsevier, vol. 211(C), pages 164-174.
  43. Meg Perry-Duxbury & Sebastian Himmler & Job Exel & Werner Brouwer, 2023. "Willingness to pay for health gains from an international integrated early warning system for infectious disease outbreaks," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(6), pages 967-986, August.
  44. Hammitt, James K., 2023. "Consistent Valuation of a Reduction in Mortality Risk using Values per Life, Life Year, and Quality-Adjusted Life Year," TSE Working Papers 23-1431, Toulouse School of Economics (TSE).
  45. Arthur E. Attema & Marieke Krol & Job Exel & Werner B. F. Brouwer, 2018. "New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 277-291, March.
  46. Jytte Seested Nielsen & Dorte Gyrd‐Hansen & Trine Kjær, 2021. "Sample restrictions and the elicitation of a constant willingness to pay per quality adjusted life year," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 923-931, May.
  47. Becchetti, Leonardo & Conzo, Gianluigi & Trovato, Giovanni, 2023. "The social value of health: A frontier analysis of life expectancy gaps across 33 European countries," Health Policy, Elsevier, vol. 133(C).
  48. McNamara, Simon & Tsuchiya, Aki & Holmes, John, 2021. "Does the UK-public's aversion to inequalities in health differ by group-labelling and health-gain type? A choice-experiment," Social Science & Medicine, Elsevier, vol. 269(C).
  49. Najme Moradi & Arash Rashidian & Shirin Nosratnejad & Alireza Olyaeemanesh & Marzieh Zanganeh & Leila Zarei, 2019. "The Worth of a Quality-Adjusted Life-Year in Patients with Diabetes: An Investigation Study using a Willingness-to-Pay Method," PharmacoEconomics - Open, Springer, vol. 3(3), pages 311-319, September.
  50. Christine Mayrhuber & Benjamin Bittschi, 2022. "Fehlzeitenreport 2022. Krankheits- und unfallbedingte Fehlzeiten in Österreich," WIFO Studies, WIFO, number 69809, April.
  51. Meng Li & Anirban Basu & Caroline S. Bennette & David L. Veenstra & Louis P. Garrison, 2019. "Do cancer treatments have option value? Real‐world evidence from metastatic melanoma," Health Economics, John Wiley & Sons, Ltd., vol. 28(7), pages 855-867, July.
  52. Pieter van Baal & Meg Perry‐Duxbury & Pieter Bakx & Matthijs Versteegh & Eddy van Doorslaer & Werner Brouwer, 2019. "A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 87-100, January.
  53. Moscelli, Giuseppe & Sayli, Melisa & Blanden, Jo & Mello, Marco & Castro-Pires, Henrique & Bojke, Chris, 2023. "Non-monetary Interventions, Workforce Retention and Hospital Quality: Evidence from the English NHS," IZA Discussion Papers 16379, Institute of Labor Economics (IZA).
  54. Herrera-Araujo, Daniel & Hammitt, James K. & Rheinberger, Christoph M., 2020. "Theoretical bounds on the value of improved health," Journal of Health Economics, Elsevier, vol. 72(C).
  55. Laura Pirhonen & Hanna Gyllensten & Andreas Fors & Kristian Bolin, 2020. "Modelling the cost-effectiveness of person-centred care for patients with acute coronary syndrome," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(9), pages 1317-1327, December.
  56. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.